drugset
drugset / Trial / NCT05405309

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT05405309 ↗

Phase 1/2 Terminated 5 enrolled University of Utah Repare Therapeutics · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open-label, multicenter, phase Ib/II study of the combination of RP-3500 and olaparib in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) patients with DDR deficiencies.

Timeline

Start
2022-09-23
Primary completion
2023-10-24
Completion
2025-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Camonsertib Small molecule 40 mg —
Subject Camonsertib Small molecule 50 mg —
Subject Camonsertib Small molecule 80 mg —
Subject Olaparib Small molecule 100 mg Oral
Subject Olaparib Small molecule 150 mg Oral

Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma